Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-T SCM cells using a Quantum pBac -based CAR-...
Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-T SCM cells using a Quantum pBac -based CAR-T engineering system
About this item
Full title
Author / Creator
Publisher
Public Library of Science
Journal title
Language
English
Formats
Publication information
Publisher
Public Library of Science
Subjects
More information
Scope and Contents
Contents
CD19-targeted chimeric antigen receptor (CAR) T cell therapies have driven a paradigm shift in the treatment of relapsed/refractory B-cell malignancies. However, >50% of CD19-CAR-T-treated patients experience progressive disease mainly due to antigen escape and low persistence. Clinical prognosis is heavily influenced by CAR-T cell function and sys...
Alternative Titles
Full title
Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-T SCM cells using a Quantum pBac -based CAR-T engineering system
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_plos_journals_3097788331
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_3097788331
Other Identifiers
E-ISSN
1932-6203
DOI
10.1371/journal.pone.0309245
